Abstract: The present invention provides an isolated DNA molecule encoding Malathion Carboxylesterase capable of hydrolysing at least one organophosphate selected from the group consisting of carboxylester organophosphates and dimethyloxon organophosphates. The DNA molecule comprises a nucleotide sequence having at least 60%, preferably at least 80% and more preferably at least 95% homology with Lc?E 7, in which the protein encoded by the DNA molecule differs from E 3 at least in the substitution of Trip at position 251 with an amino acid selected from the group consisting of Leu, Ser, Ala, Ile, Val, Thr, Cys, Met and Gly. The preferred substituents are Leu and Ser.

Abstract: The present invention is drawn to a gene comprising a polynucleotide encoding a polypeptide composed of an amino acid sequence represented by SEQ ID NO: 1; a gene expression product produced through expression of the gene; a recombinant expression vector including the gene; a host cell (transformant) harboring the recombinant expression vector; a protein composed of an amino acid having an amino acid sequence represented by SEQ ID NO: 1; a therapeutic or preventive composition for hypoglycemia containing as an active ingredient the above-mentioned gene or protein; and an antibody capable of binding to the protein. Through use of the gene or an expression product thereof of the present invention, it is possible to elucidate the pathology of diabetes and develop drugs for treatment and prevention of diabetes via a new action mechanism.

Abstract: An isolated and purified ?-N-acetyl-D-galactosaminidase from Clostridium perfringens and homologs thereof are disclosed. A method for purifying and isolating the ?-N-acetylgalactosaminidase from Clostridium perfringens by removing neuramidases is disclosed. A process for using the ?-N-acetylgalactosaminidase from Clostridium perfringens in altering type A blood cells to type O blood cells is disclosed. A process for altering cells expressing blood group A epitope by using ?-N-acetylgalactosaminidase isolated from Clostridium perfringens in altering the cells expressing blood group A epitope to cells expressing blood group O epitope is disclosed.

Abstract: The present invention relates to a novel process for the preparation of (S)- or (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid and to novel microorganisms capable of utilizing the propionamide of the formula in the form of the racemate or of its optically active isomers as the sole nitrogen source.

Abstract: A DNA encoding a novel protein SMAP-1 having a signal sequence was successfully isolated by screening a cDNA library derived from human fetal hepatocyte using the TMT method developed originally by the inventors. Based on the expression pattern and structural properties, SMAP-1 was suggested to be a molecule playing an important role in living cells.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phospholipase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the phospholipase peptides, and methods of identifying modulators of the phospholipase peptides.

Abstract: The present invention is directed to thermostable xylanase enzymes are suitable for feed pelleting applications. The novel xylanase enzymes comprise at least 40% of their optimal activity from a pH range from about pH 3.5 to about pH 6.0, and from about 40 to about 60° C., and exhibit at least 30% of their optimal activity after a pre-incubation step for 30 minutes at 70° C. in the presence of 40% glycerol. Also disclosed are modified xylanase molecules comprising either a basic amino acid at position 162 (TrX numbering), or its equivalent position in other xylanase molecules, at least one disulfide bridge, or a combination thereof. The thermostable xylanase molecules of the present invention have a physiological temperature and pH optima and are useful as animal feeds additives since they can withstand the heat associated with feed sterilization and pellet formation, yet they exhibit optimal activity within an animal to aid in breakdown of ingested feed.

Abstract: The present invention provides a novel endoglucanase nucleic acid sequence, designated egl6, and the corresponding EGVI amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding EGVI, recombinant EGVI proteins and methods for producing the same.

Abstract: This invention relates to the isolation of nucleic acid fragments from Methylamons sp. that encode enzymes involved in denitrification. The enzymes arc useful in denitrification reactions and for the identification of other denitrifying bacteria. In addition, this invention also relates to the construction of chimeric genes encoding all or a substantial portion of the present genes in sense or antisense orientation, wherein the expression of the chimeric genes results in production of altered levels of the present gene products in the recombinant host.

Abstract: Modified water-soluble glucose dehydrogenases having pyrrolo-quinoline quinone as a coenzyme are provided wherein at least one amino acid residue is replaced by another amino acid residue in a specific region. Modified water-soluble PQQGDHs of the present invention have improved affinity for glucose.

Abstract: The present invention provides a novel endoglucanase nucleic acid sequence, designated egl8, and the corresponding EGVIII amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding EGVIII, recombinant EGVIII proteins and methods for producing the same.

Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.

Abstract: The present invention provides a novel ?-glucosidase nucleic acid sequence, designated bgl4, and the corresponding BGL4 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding BGL4, recombinant BGL4 proteins and methods for producing the same.

Abstract: The present invention provides a novel endoglucanase nucleic acid sequence, designated egl7, and the corresponding EGVII amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding EGVII, recombinant EGVII proteins and methods for producing the same.

Abstract: The present invention provides a recombinant ?-L-iduronidase and biologically active fragments and mutants thereof, methods to produce and purify this enzyme as well as methods to treat certain genetic disorders including-?-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1).

Abstract: Detergent composition comprising fusion protein comprising a cellulose binding domain and a domain having a high binding affinity for another ligand. Preferably, the domain having a high binding affinity is directed at a Benefit Agent.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.

Abstract: The present invention relates, in general, to vectors comprising Ketogulonigenium replicons. More specifically, the present invention relates to vectors comprising a Ketogulonigenium replicon found on the endogenous plasmid contained in Deposit No. NRRL B-30035.

Abstract: The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying modulators of the protease peptides.